RT info:eu-repo/semantics/article
T1 Relationship between adiponectin and muscle mass in patients with metabolic syndrome and obesity
A1 Luis Román, Daniel Antonio de
A1 Primo, David
A1 Izaola Jauregui, Olatz
A1 López Gómez, Juan José
K1 Adiponectin
K1 Metabolic syndrome
K1 Obesity
K1 Skeletal muscle mass index
K1 32 Ciencias Médicas
AB Background: Adiponectin is one of the most important adipokines in human beings. Obesity and sarcopenia are associated with a low-level chronic inflammatory status, and adiponectin plays an anti-inflammatory role.Aims: The objective of the current work was to study the association between muscle mass, determined via bioelectrical impedance (BIA), and circulating adiponectin levels among obese patients with metabolic syndrome who are older than 60 years of age.Methods: We performed a cross-sectional study incorporating 651 patients with obesity and metabolic syndrome. Anthropometric data, BIA data (total fat mass (FM), fat-free mass (FFM), fat-free mass index (FFMi), skeletal muscle mass (SMM) and skeletal muscle mass index (SMMi)), arterial pressure, HOMA-IR (homeostasis model assessment of insulin resistance), and biochemical parameters were recorded.Results: The patients were separated into two groups based on their median SMMi (skeletal muscle mass index) levels. The low-SMMi group presented adiponectin levels that were higher than those in the high-SMMi group (delta value: 4.8 + 0.7 ng/dl: p = 0.02). Serum adiponectin values were negatively correlated with fat mass (FM), fat-free mass (FFM), fat-free mass index (FFMi), SMM, and SMMi. Adiponectin presented a negative correlation with HOMA-IR and a positive correlation with HDL-cholesterol. In the final multivariate model using SMMi as a dependent variable, adiponectin levels explained 18 % of the variability (Beta −0.49, CI95% −0.89 to −0.16) after adjusting for age and gender.Conclusions: Serum adiponectin levels are negatively associated with low skeletal muscle mass among obese subjects with metabolic syndrome who are older than 60 years of age.
PB Elsevier
SN 1056-8727
YR 2024
FD 2024
LK https://uvadoc.uva.es/handle/10324/72933
UL https://uvadoc.uva.es/handle/10324/72933
LA eng
NO Journal of Diabetes and its Complications, abril 2024, vol. 38, n. 4, 108706
NO Producción Científica
DS UVaDOC
RD 05-feb-2025